Oncology

View All

Antibody Drug Conjugates for Cancer Treatment in Asia Healthcare Market
Antibody-Drug Conjugate: The Smart Biological Bomb

Antibody-drug conjugate (ADCs) is a new emerging class of highly potent pharmaceutical drugs, which is a great combination of chemotherapy and immunotherapy. Over the past couple of decades, antibody-drug conjugates have revolutionized the field of cancer chemotherapy. ADCs are composed of 3 parts: an antibody drug...

Find More

Non-Small Cell Lung Cancer Treatment Market Outlook
Novel Insights Into The Non-Small Cell Lung Cancer Market

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of all lung cancers. As per the American Cancer Society, almost 230K new cases were diagnosed in 2022 alone, and almost 130K deaths from lung cancer were recorded in the same year.  Studies show that non-small cel...

Find More

Digital Health in the Field of Oncology
Emerging Role of Digital Health in the Field of Oncology

The growth and development in the Digital health technologies, such as mobile health (mHealth) apps, electronic health records (EHRs), electronic medical records (EMRs), wearable devices, telehealth, and telemedicine, as well as personalized medicine, have immensely transformed the healthcare industry and its marke...

Find More

bispecific-antibodies
Rise In Bispecific Antibodies Utilization As Antibody Therapeutics

Bispecific Antibodies (BsAbs) are antibodies that contain two different antigens or have two different epitopes on the same antigen. It is observed for Bispecific Antibodies in clinical trials that the therapeutic effects of these are considerably higher than those of monoclonal antibodies (MoAbs). There are a vast...

Find More

AACR 2022 KRAS
AACR 2022: Novartis shifting focus towards directly targeting KRASG12c after disappointment from SHP2 inhibitor, TNO155.

Post Lumakras ‘approval,  Adagrasib’s PDUFA date, Novartis now ready to enter the KRASG12C space Novartis is now heading towards its unique KRASG12C inhibitor in patients with advanced non-small cell lung cancer (NSCLC). The company presented the promising preliminary data (Phase Ib) from the KontRASt-01 study e...

Find More

AACR 2022 - LAG 3 Immunotherapy
AACR 2022: LAG-3, one of the most trending Next-generation Immunotherapy

Updates on F-star Therapeutics’ and Akeso’s Bi-specific Antibody targeting LAG-3 and PD-L1 F-star Therapeutics presented the preclinical mechanistic data on the Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022. The data demonstrated that the tetravalent and unique structure of FS118 played a ...

Find More

ASCO GU 2022 - Urothelial Carcinoma
Data readout of potential ADCs: Enhertu gears up for Urothelial Carcinoma Market now

Enhertu with Opdivo exhibited clinical efficacy with an ORR of 36.7% in HER2+ urothelial cancer in Phase Ib study On the second day of ASCO-GU 2022, the rapid abstract session highlighted the results from the DS8201-A-U105 trial (NCT03523572; Active, not recruiting) of Enhertu (trastuzumab deruxtecan) with Opdiv...

Find More

PARP Inhibitors in Urothelial Carcinoma
PARP inhibitors in Urothelial carcinoma (UC): Hit or miss?

Chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates are being used for treating Urothelial Carcinoma(UC) patients and now PARP inhibitors are being studied in UC in the neoadjuvant, first-line, maintenance therapy, and subsequent lines of the setting. It is worth n...

Find More

Renal Cell Carcinoma Highlights- ASCO
ASCO GU 2022: Renal Cell Carcinoma Highlights

Phase II study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma Based on the findings from the Phase II study (NCT04022343), neoadjuvant cabozantinib was safe and induced a reduction in tumor size in all patients with locally advanced nonmetastatic ccRC...

Find More

Bladder Cancer Highlights ASCO
Seagen/Astellas plans to expand their Antibody Drug Conjugate (ADC), Padcev in additional bladder cancer settings?

Padcev (Enfortumab vedotin) for the treatment of locally advanced or metastatic urothelial cancer, Adcetris (Brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas, and Tivdak (Tisotumab vedotin) for the treatment of recurrent or metastatic cervical cancer are the three ADCs that Seage...

Find More